evacetrapib

From Aaushi
Jump to navigation Jump to search

Introduction

Investigational drug.

Indications

Dosage

  • 100-500 mg QD
  • 100 mg QD when used in combination with statin

Mechanism of action

More general terms

References

  1. Nicholls SJ et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011 Nov 16; 306:2099. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22089718 <Internet> http://jama.ama-assn.org/content/306/19/2099.full
    Cannon CP. High-density lipoprotein cholesterol as the holy grail. JAMA 2011 Nov 16; 306:2153. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22089726
  2. 2.0 2.1 Lincoff AM, Nicholls SJ, Riesmeyer JS et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017 May 18; 376:1933. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28514624 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1609581